Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Accumulated Expenses (2016 - 2025)

Macrogenics (MGNX) has disclosed Accumulated Expenses for 14 consecutive years, with $22.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 24.22% to $22.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.2 million through Dec 2025, down 24.22% year-over-year, with the annual reading at $22.2 million for FY2025, 24.22% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $22.2 million at Macrogenics, down from $23.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $41.9 million in Q3 2021, with the low at $18.1 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $28.7 million, with a median of $28.0 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses tumbled 35.62% in 2024, then soared 53.39% in 2025.
  • Over 5 years, Accumulated Expenses stood at $33.8 million in 2021, then decreased by 14.09% to $29.0 million in 2022, then decreased by 16.41% to $24.2 million in 2023, then rose by 21.02% to $29.3 million in 2024, then dropped by 24.22% to $22.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $22.2 million, $23.1 million, and $21.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.